Anti-CGRP monoclonal antibodies in migraine: current perspectives

Internal and Emergency Medicine

Volumn 11, Issue 8, 2016, Pages 1045-1057

  Giamberardino, Maria Adele ^a   Affaitati, Giannapia ^a   Curto, Martina ^b,c,d,e   Negro, Andrea ^b,c   Costantini, Raffaele ^a   Martelletti, Paolo ^b,c  

^a GABRIELE D'ANNUNZIO UNIVERSITY   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d HARVARD MEDICAL SCHOOL   (United States)

^e MCLEAN HOSPITAL   (United States)

Author keywords

CGRP; Migraine; Migraine prophylaxis; Monoclonal antibodies against CGRP

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE RECEPTOR; MONOCLONAL ANTIBODY; TEV-48125;

ANALGESIA; DRUG EFFECTS; HUMAN; MIGRAINE DISORDERS; PROCEDURES;

ANTIBODIES, MONOCLONAL; HUMANS; MIGRAINE DISORDERS; PAIN MANAGEMENT; RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE;

EID: 84976331079     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-016-1489-4     Document Type: Review

References (97)

1. Global Burden of Disease Study 2013 Collaborators (2015) Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet (published online June 8, 2015 at http://dx.doi.org/10.1016/S0140-6736(15)60692-4)
2. Pieroni A, Caso V, Cittadini E, Hamam M, Paciaroni M (2012) A case of typical headache with an atypical diagnosis. Intern Emerg Med 7(Suppl 2):S121–S123
3. Steiner TJ, Birbeck GL, Jensen RH, Katsarava Z, Stovner LJ, Martelletti P (2015) Headache disorders are third cause of disability worldwide. J Headache Pain 16:58
4. Giamberardino MA, Martelletti P (2015) Emerging drugs for migraine treatment. Expert Opin Emerg Drugs 20:137–147
5. Martelletti P (2015) The therapeutic armamentarium in migraine is quite elderly. Expert Opin Drug Metab Toxicol 11:175–177
6. Curto M, Lionetto L, Fazio F, Mitsikostas DD, Martelletti P (2015) Fathoming the kynurenine pathway in migraine: why understanding the enzymatic cascades is still critically important. Intern Emerg Med 10(4):413–421
7. Bigal ME, Walter S, Rapoport AM (2013) Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development. Headache 53(8):1230–1244
8. Diener HC, Charles A, Goadsby PJ, Holle D (2015) New therapeutic approaches for the prevention and treatment of migraine. Lancet Neurol 14:1010–1022
9. Edvinsson L (2015) The journey to establish CGRP as a migraine Target: A Retrospective View. Headache 55:1249–1255
10. Edvinsson L (2015) CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment. Br J Clin Pharmacol 80:193–199
11. Karsan N, Goadsby PJ (2015) Calcitonin gene-related peptide and migraine. Curr Opin Neurol 28:250–254
12. Mitsikostas DD, Rapoport AM (2015) New players in the preventive treatment of migraine. MC Med 13:279
13. Russo AF (2015) Calcitonin gene-related peptide (CGRP): a new target for migraine. Annu Rev Pharmacol Toxicol 55:533–552
14. Sabato D, Lionetto L, Martelletti P (2015) The therapeutic potential of novel anti-migraine acute therapies. Expert Opin Investig Drugs 24:141–144
15. Schuster NM, Vollbracht S, Rapoport AM (2015) Emerging treatments for the primary headache disorders. Neurol Sci 36:109–113
16. Wrobel Goldberg S, Silberstein SD (2015) Targeting CGRP: a new era for migraine treatment. CNS Drugs 29:443–452
17. Bigal ME, Walter S, Rapoport AM (2015) Therapeutic antibodies against CGRP or its receptor. Br J Clin Pharmacol 79:886–895
18. Bigal ME, Walter S (2014) Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity. CNS Drugs 28:389–399
19. Edvinsson L, Warfvinge K (2013) CGRP receptor antagonism and migraine therapy. Curr Protein Pept Sci 14(5):386–392
20. Negro A, Lionetto L, Simmaco M, Martelletti P (2012) CGRP receptor antagonists: an expanding drug class for acute migraine? Expert Opin Investig Drugs 21:807–818
21. Silberstein SD (2013) Emerging target-based paradigms to prevent and treat migraine. Clin Pharmacol Ther 93:78–85
22. Silberstein SD (2015) Therapeutic monoclonal antibodies for migraine. US Neurol US Neurology 11(1):64–65
23. Silberstein S, Lenz R, Xu C (2015) Therapeutic monoclonal antibodies: what headache specialists need to know. Headache 55:1171–1182
24. Headache Classification of the International Headache Society (2013) The international classification of headache disorders, 3rd edition (beta version). Cephalalgia 33:627–808
25. Manzoni GC, Torelli P (2010) Epidemiological classification and social impact of chronic headache. Intern Emerg Med 5(Suppl 1):S1–S5
26. Negro A, D’Alonzo L, Martelletti P (2010) Chronic migraine: comorbidities, risk factors, and rehabilitation. Intern Emerg Med 5(Suppl 1):S13–S19
27. Farinelli I, Dionisi I, Martelletti P (2011) Rehabilitating chronic migraine complicated by medication overuse headaches: how can we prevent migraine relapse? Intern Emerg Med 6(1):23–28
28. Geppetti P, De Cesaris F, Nicoletti P, Benemei S (2010) Chronic headaches and medication overuse. Intern Emerg Med 5(Suppl 1):S7–S11
29. Giamberardino MA, Mitsikostas DD, Martelletti P (2015) Update on medication-overuse headache and its treatment. Curr Treat Options Neurol 17:368
30. Bartolini M, Giamberardino MA, Lisotto C, Martelletti P, Moscato D, Panascia B, Savi L, Pini LA, Sances G, Santoro P, Zanchin G, Omboni S, Ferrari MD, Brighina F, Fierro B (2011) A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine. J Headache Pain 12:361–368
31. Loder E (2010) Triptan therapy in migraine. N Engl J Med 363:63–70
32. Ungprasert P (2016) NSAIDs and cardiovascular disease: time to say no to diclofenac. Intern Emerg Med 11(1):1–2
33. Affaitati G, Costantini R, Fabrizio A, Lapenna D, Tafuri E, Giamberardino MA (2011) Effects of treatment of peripheral pain generators in fibromyalgia patients. Eur J Pain 15(1):61–69
34. Affaitati G, Fabrizio A, Savini A, Lerza R, Tafuri E, Costantini R, Lapenna D, Giamberardino MA (2009) A randomized, controlled study comparing a lidocaine patch, a placebo patch, and anesthetic injection for treatment of trigger points in patients with myofascial pain syndrome: evaluation of pain and somatic pain thresholds. Clin Ther 31(4):705–720
35. Giamberardino MA, Affaitati G, Costantini R (2006) Chapter 24 referred pain from internal organs. Handb Clin Neurol 81:343–361
36. Giamberardino MA, Affaitati G, Costantini R (2010) Visceral referred pain. J Musculoskelet Pain 18:403–410
37. Giamberardino MA, Affaitati G, Fabrizio A, Costantini R (2011) Myofascial pain syndromes and their evaluation. Best Pract Res Clin Rheumatol 25:185–198
38. Giamberardino MA, Affaitati G, Fabrizio A, Costantini R (2011) Effects of treatment of myofascial trigger points on the pain of fibromyalgia. Curr Pain Headache Rep 15:393–399
39. Giamberardino MA, Affaitati G, Martelletti P, Tana C, Negro A, Lapenna D, Curto M, Schiavone C, Stellin L, Cipollone F, Costantini R (2016) Impact of migraine on fibromyalgia symptoms. J Headache Pain. doi:10.1186/s10194-016-0619-8 (Epub 2016 Mar 22)
40. Giamberardino MA, Costantini R, Affaitati G, Fabrizio A, Lapenna D, Tafuri E, Mezzetti A (2010) Viscero-visceral hyperalgesia: characterization in different clinical models. Pain 151(2):307–322
41. Giamberardino MA, Tafuri E, Savini A, Fabrizio A, Affaitati G, Lerza R, Di Ianni L, Lapenna D, Mezzetti A (2007) Contribution of myofascial trigger points to migraine symptoms. J Pain 8:869–878
42. Giamberardino MA, Tana C, Costantini R (2014) Pain thresholds in women with chronic pelvic pain. Curr Opin Obstet Gynecol 26:253–259
43. Tana C, Santilli F, Martelletti P, di Vincenzo A, Cipollone F, Davì G, Giamberardino MA (2015) Correlation between Migraine severity and cholesterol levels. Pain Pract 15:662–670
44. Tana C, Tafuri E, Tana M, Martelletti P, Negro A, Affaitati G, Fabrizio A, Costantini R, Mezzetti A, Giamberardino MA (2013) New insights into the cardiovascular risk of migraine and the role of white matter hyperintensities: is gold all that glitters? J Headache Pain 1(14):9
45. Bagnato F, Good J (2016) The use of antiepileptics in migraine prophylaxis. Headache 56(3):603–615
46. Goadsby PJ (2009) The vascular theory of migraine—a great story wrecked by the facts. Brain 132:6–7
47. Silberstein SD (2004) Migraine pathophysiology and its clinical implications. Cephalalgia 24(Suppl 2):2–7
48. Durham PL (2006) Calcitonin gene-related peptide (CGRP) and migraine. Headache 46(Suppl 1):S3–S8
49. Messlinger K (2009) Migraine: where and how does the pain originate? Exp Brain Res 196:179–193
50. Goadsby PJ (2007) Recent advances in understanding migraine mechanisms, molecules and therapeutics. Trends Mol Med 13:39–44
51. Cao T, Pinter E, Al Rashed S, Gerard N, Hoult JR, Brain SD (2000) Neurokinin-1 receptor agonists are involved in mediating neutrophil accumulation in the inflamed, but not normal, cutaneous microvasculature: an in vivo study using neurokinin-1 receptor knockout mice. J Immunol 164:5424–5429
52. Markowitz S, Saito K, Moskowitz MA (1987) Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain. J Neurosci 7:4129–4136
53. Raddant AC, Russo AF (2011) Calcitonin gene-related peptide in migraine: intersection of peripheral inflammation and central modulation. Expert Rev Mol Med 13:e36
54. Akerman S, Holland PR, Goadsby PJ (2011) Diencephalic and brainstem mechanisms in migraine. Nat Rev Neurosci 12:570–584
55. Rosenfeld MG, Mermod JJ, Amara SG, Swanson LW, Sawchenko PE, Rivier J, Vale WW, Evans RM (1983) Production of a novel neuropeptide encoded by the calcitonin gene via tissue specific RNA processing. Nature 304:129–135
56. Eftekhari S, Salvatore CA, Johansson S, Chen TB, Zeng Z, Edvinsson L (2015) Localization of CGRP, CGRP receptor, PACAP and glutamate in trigeminal ganglion. Relation to the bloodbrain barrier. Brain Res 1600:93–109
57. Eftekhari S, Warfvinge K, Blixt FW, Edvinsson L (2013) Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system. J Pain 14:1289–1303
58. Mulderry PK, Ghatei MA, Bishop AE, Allen YS, Polak JM, Bloom SR (1985) Distribution and chromatographic characterisation of CGRP-like immunoreactivity in the brain and gut of the rat. Regul Pept 12:133–143
59. Wimalawansa SJ, Morris HR, Etienne A, Blench I, Panico M, MacIntyre I (1990) Isolation, purification and characterization of beta-hCGRP from human spinal cord. Biochem Biophys Res Commun 167:993–1000
60. Russell FA, King R, Smillie S-J, Kodji X (2014) Calcitonin gene-related peptide: physiology and pathophysiology. Brain Physiol Rev 94:1099–1142
61. Barwell J, Wootten D, Simms J, Hay DL, Poyner DR (2012) RAMPs and CGRP receptors. Adv Exp Med Biol 744:13–24
62. Marvizón JC, Pérez OA, Song B, Chen W, Bunnett NW, Grady EF, Todd AJ (2007) Calcitonin receptor-like receptor and receptor activity modifying protein 1 in the rat dorsal horn: localization in glutamatergic presynaptic terminals containing opioids and adrenergic alpha2C receptors. Neuroscience 148:250–265
63. Oku R, Satoh M, Fujii N, Otaka A, Yajima H, Takagi H (1987) Calcitonin gene-related peptide promotes mechanical nociception by potentiating release of substance P from the spinal dorsal horn in rats. Brain Res 403:350–354
64. Seybold VS (2009) The role of peptides in central sensitization. Handb Exp Pharmacol 194:451–491
65. Walker CS, Hay DL (2013) CGRP in the trigeminovascular system: a role for CGRP, adrenomedullin and amylin receptors? Br J Pharmacol 170(7):1293–1307
66. Gallai V, Sarchielli P, Floridi A, Franceschini M, Codini M, Glioti G, Trequattrini A, Palumbo R (1995) Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia 15:384–390
67. Goadsby PJ, Edvinsson L (1993) The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 33:48–56
68. Goadsby PJ, Edvinsson L, Ekman R (1990) Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 28:183–187
69. Juhasz G, Zsombok T, Jakab B, Nemeth J, Szolcsanyi J, Bagdy G (2005) Sumatriptan causes parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced migraine attack. Cephalalgia 25:179–183
70. Sarchielli P, Alberti A, Codini M, Floridi A, Gallai V (2000) Nitric oxide metabolites, prostaglandins and trigeminal vasoactive peptides in internal jugular vein blood during spontaneous migraine attacks. Cephalalgia 20:907–918
71. Asghar MS, Hansen AE, Amin FM, van der Geest RJ, Koning P, Larsson HB, Olesen J, Ashina M (2011) Evidence for a vascular factor in migraine. Ann Neurol 4:635–645
72. Hansen JM, Hauge AW, Olesen J, Ashina M (2010) Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia 30:1179–1186
73. Lassen L, Haderslev P, Jacobsen V, Iversen H, Sperling B, Olesen J (2002) CGRP may play a causative role in migraine. Cephalalgia 2:54–61
74. Lassen LH, Jacobsen VB, Haderslev PA, Sperling B, Iversen HK, Olesen J, Tfelt-Hansen P (2008) Involvement of calcitonin gene-related peptide in migraine: regional cerebral blood flow and blood flow velocity in migraine patients. J Headache Pain 9:151–157
75. Petersen KA, Lassen LH, Birk S, Lesko L, Olesen J (2005) BIBN4096BS antagonizes human alpha-calcitonin gene related peptide-induced headache and extracerebral artery dilatation. Clin Pharmacol Ther 3:202–213
76. Cernuda-Morollón E, Larrosa D, Ramón C, Vega J, Martínez-Camblor P, Pascual J (2013) Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology 81:1191–1196
77. Strassman AM, Raymond SA, Burstein R (1996) Sensitization of meningeal sensory neurons and the origin of headaches. Nature 384:560–564
78. Recober A, Kuburas A, Zhang Z, Wemmie JA, Anderson MG, Russo AF (2009) Role of calcitonin gene-related peptide in light-aversive behavior: implications for migraine. J Neurosci 29:8798–8804
79. Hougaard A, Tfelt-Hansen P (2015) Review of dose-response curves for acute antimigraine drugs: triptans, 5-HT1F agonists and CGRP antagonists. Expert Opin Drug Metab Toxicol 11:1409–1418
80. Neal F, Arnold J, Rossant CJ, Podichetty S, Lowne D, Dobson C, Wilkinson T, Colley C, Howes R, Vaughan TJ (2016) Isolation of potent CGRP neutralizing antibodies using four simple assays. J Biomol Screen 21(1):24–34
81. Vermeersch S, Benschop RJ, Van Hecken A, Monteith D, Wroblewski VJ, Grayzel D, de Hoon J, Collins EC (2015) translational pharmacodynamics of calcitonin gene-related peptide monoclonal antibody LY2951742 in a capsaicin-induced dermal blood flow model. J Pharmacol Exp Ther 354:350–357
82. Dodick DW, Goadsby PJ, Spierings EL, Scherer JC, Sweeney SP, Grayzel DS (2014) Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol 13:885–892
83. Dodick DW, Goadsby PJ, Silberstein SD, Lipton RB, Olesen J, Ashina M, Wilks K, Kudrow D, Kroll R, Kohrman B, Bargar R, Hirman J, Smith J (2014) ALD403 study investigators. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol 13:1100–1107
84. Goadsby PJ, Dodick DW, Silberstein SD, Lipton RB, Olesen J, Ashina M, Wilks K, Kudrow D, Kroll R, Kohrman B, Bargar R, Hirman J, Smith J (2015) Randomized, double-blind, placebo-controlled trial of ALD403, an anti-CGRP antibody in the prevention of frequent episodic migraine. In: 17th Congress of the International Headache Society, Valencia, 2015
85. Walter S, Alibhoy A, Escandon R, Bigal ME (2014) Evaluation of cardiovascular parameters in cynomolgus monkeys following IV administration of LBR-101, a monoclonal antibody against calcitonin gene-related peptide. MAbs 6:871–878
86. Bigal ME, Escandon R, Bronson M, Walter S, Sudworth M, Huggins JP, Garzone P (2013) Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: results of the Phase 1 program. Cephalalgia 34:483–492
87. Bigal ME, Walter S, Bronson M, Alibhoy A, Escandon R (2014) Cardiovascular and hemodynamic parameters in women following prolonged CGRP inhibition using LBR-101, a monoclonal antibody against CGRP. Cephalalgia 34:968–976
88. Walter S, Bigal ME (2015) TEV-48125: a review of a monoclonal CGRP antibody in development for the preventive treatment of migraine. Curr Pain Headache Rep 19:6
89. Bigal ME, Dodick DW, Rapoport AM, Silberstein SD, Ma Y, Yang R, Loupe PS, Burstein R, Newman LC, Lipton RB (2015) Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 14:1081–1090
90. Bigal ME, Edvinsson L, Rapoport AM, Lipton RB, Spierings EL, Diener HC, Burstein R, Loupe PS, Ma Y, Yang R, Silberstein SD (2015) Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 14:1091–1100
91. Lenz R, Silberstein S, Dodick D, Reuter U, Ashina M, Saper J, Cady R, Chon Y, Dietrich J, Sun H (2015) Results of a randomized, double-blind, placebo-controlled, phase 2 study to evaluate the efficacy and safety of AMG 334 for the prevention of episodic migraine. In: 17th Congress of the International Headache Society, Valencia, 2015
92. Sun H, Dodick DW, Silberstein S, Goadsby PJ, Reuter U, Ashina M, Saper J, Cady R, Chon Y, Dietrich J, Lenz R (2016) Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 15(4):382–390
93. Zeller J, Poulsen KT, Sutton JE, Abdiche YN, Collier S, Chopra R, Garcia CA, Pons J, Rosenthal A, Shelton DL (2008) CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat. Br J Pharmacol 155:1093–1103
94. Pascual J (2015) CGRP antibodies: the Holy Grail for migraine prevention? Lancet Neurol 14:1066–1067
95. Gazerani P, Cairns BE (2013) New insight in migraine pathogenesis: Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) in the circulation after sumatriptan. Scand J Pain 4:208–210
96. Tfelt-Hansen P (2015) Site of effect of LY2951742 for migraine prophylaxis. Lancet Neurol 14:31–32
97. Edvinsson L, Ekman R, Uddman R, Kingman TA, McCulloch J (1984) Calcitonin gene related peptide (CGRP)-containing perivascular fibres in brain vessels: Localization and its effects in vitro and in situ. In: Presented at INSERM Symposium no. 25: Regulatory Peptides in Digestive, Nervous and Endocrine Systems. CNRS, Paris